RET
Stories
-
Hoffmann-La Roche posts results of Phase 3 alectinib rollover study
Results for the study were first posted on ClinicalTrials.gov on October 9, 2026. The completed Phase 3 rollover study enrolled 50 participants and compared alectinib with crizotinib in patients with ALK- or RET-positive cancer.